| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.7M | — | +9.6% |
| SG&A Expense | $2.4M | — | +20.8% |
| Operating Income | -$5.1M | — | -14.6% |
| Pre-tax Income | -$5.0M | — | +53.6% |
| Net Income | -$5.0M | — | +54.4% |
| EPS (Basic) | -$0.15 | — | +98.2% |
| EPS (Diluted) | -$0.15 | — | +98.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $13.2M | +102.7% | -24.6% |
| Current Assets | $15.0M | +78.0% | -21.7% |
| Total Assets | $95.2M | +5.6% | -1.8% |
| Current Liabilities | $2.6M | -16.3% | -0.8% |
| Total Liabilities | $14.6M | -4.5% | +2.5% |
| Stockholders' Equity | $80.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.6M | — | +2.0% |
| Financing Cash Flow | $11.3M | — | +53.2% |
| +1037.6% |